SANTA BARBARA, Calif., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Sientra, Inc. (Nasdaq:SIEN), a medical aesthetics company, announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. In addition, Sientra has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the same price. The shares are expected to begin trading on the NASDAQ Global Select Market on October 29, 2014 under the ticker symbol "SIEN". The offering is expected to close on November 3, 2014, subject to customary closing conditions.
Piper Jaffray and Stifel are acting as joint book-running managers for the offering. Leerink Partners and William Blair are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 28, 2014. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering, when available, may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, and by e-mail at prospectus@pjc.com; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.